Johnson & Johnson (JNJ) News
Filter JNJ News Items
JNJ News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest JNJ News From Around the Web
Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
Johnson & Johnson (JNJ) closed at $144.89 in the latest trading session, marking a +0.23% move from the prior day.
Revoking Hong Kong’s special status is Trump’s ‘nuclear option’ that could trigger irrevocable U.S.-China split, analysts warn
Secretary of State Mike Pompeo declared Hong Kong to be no longer autonomous from China Wednesday, a move that further increases U.S.-China tensions and could pave the way for changes to U.S. policy toward Hong Kong that could have massive ramifications for the Hong Kong, Chinese and American economies.
The "forever" part means investors have to think about the longevity of payout growth as well as reliable payments.
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
Major pharma companies rejected a 2017 EU proposal that could let vaccines for viruses like the coronavirus be developed before an outbreak
A 2017 proposal that would speed up vaccine production in the EU was blocked by major pharmaceutical companies, The Guardian reported . The proposal would fund improvements to testing, potentially allowing approval to be fast-tracked and for vaccines against viruses like the novel coronavirus to be developed before an outbreak begins. But it was rejected by the pharmaceutical companies on the IMI, a body dedicated to improving the EU's pharmaceutical research. Representatives of a group that includes GlaxoSmithKline, Novartis, Pfizer, and Johnson & Johnson are part of that body, The Guardian reported . The IMI rejected the claim that it has focused on other illnesses to the detriment of the coronavirus, pointing to investments it has made in vaccines and in light of the Ebola outbreak. ...
North American Market for Baby & Adult Diapers Worth $15 Billion by 2025 - Key Players are Kimberly Clark, Procter & Gamble, SCA Hygiene and Johnson & Johnson
DUBLIN, May 22, 2020 /PRNewswire/ -- The "North America Baby & Adult Diaper Market Outlook, 2025" report has been added to ResearchAndMarkets.com's offering. The North American diaper market is estimated to reach US$14.99 billion in the year 2025 with a growth of more than 2% (CAGR). This…
Good day, Gartner, Inc. released the results from its annual Supply Chain Top 25 , identifying supply chain leaders and highlighting their best practices. Cisco Systems scored the top spot in the ranking, followed by Colgate-Palmolive, Johnson & Johnson, Schneider Electric, and Nestlé. Six new companies joined this year's list – Lenovo, AbbVie, British American Tobacco, Reckitt Benckiser, Biogen, and Kimberly-Clark. Three key trends stand out this year for the companies that made the list, Gartner said in a press release. They use a "language of purpose," recognize that problem solving requires partnership with others in the community and were early and frequent adopters of digital technologies. Did you know? Gross margins for truckload activity managed by 3PLs declined 210 basis points...
J&J will stop selling its talk based Baby Powder because of 16.000 lawsuits claiming it is carcinogenic
Johnson & Johnson on Tuesday announced that it would stop selling its talc-based Johnson's Baby Powder in the United States and Canada, saying it was part of a broad reassessment of its consumer product portfolio prompted by the coronavirus pandemic.
JNJ stock is now 0.72% up. Johnson & Johnson announced that it will stop selling its talc baby powder in the U.S. and also in Canada.
FAIRLESS HILLS, Pa. — Johnson & Johnson is ending sales of its iconic talc-based Johnson’s Baby Powder in the U.S. and Canada, where demand has dwindled amid thousands of lawsuits claiming it has caused cancer. The world’s biggest maker of health care products said Tuesday the talc-based powder will still be sold outside the U.S….